Halozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year High at $20.25

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) reached a new 52-week high on Tuesday . The stock traded as high as $20.25 and last traded at $19.07, with a volume of 10633 shares trading hands. The stock had previously closed at $18.77.

Several research firms recently weighed in on HALO. Barclays upgraded Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and decreased their price objective for the company from $17.00 to $16.00 in a report on Tuesday, November 5th. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a report on Thursday, November 7th. Goldman Sachs Group began coverage on Halozyme Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $24.00 price objective for the company. BMO Capital Markets upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $17.00 to $24.00 in a report on Thursday, January 9th. Finally, ValuEngine downgraded Halozyme Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Halozyme Therapeutics currently has an average rating of “Buy” and an average target price of $21.67.

The firm has a market cap of $2.80 billion, a PE ratio of -35.22 and a beta of 1.86. The company has a quick ratio of 2.83, a current ratio of 3.17 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average price of $18.67 and a two-hundred day moving average price of $17.02.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05). Halozyme Therapeutics had a negative return on equity of 15.76% and a negative net margin of 19.73%. The business had revenue of $46.20 million for the quarter, compared to analysts’ expectations of $54.96 million. During the same quarter in the previous year, the firm posted ($0.19) EPS. Halozyme Therapeutics’s revenue was up 80.5% on a year-over-year basis. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post -0.42 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. boosted its position in Halozyme Therapeutics by 25.2% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 967 shares during the last quarter. NumerixS Investment Technologies Inc boosted its position in Halozyme Therapeutics by 70.7% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,390 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 990 shares in the last quarter. Colony Group LLC boosted its position in Halozyme Therapeutics by 1.6% in the 2nd quarter. Colony Group LLC now owns 70,490 shares of the biopharmaceutical company’s stock worth $1,211,000 after purchasing an additional 1,095 shares in the last quarter. SG Americas Securities LLC boosted its position in Halozyme Therapeutics by 23.4% in the 3rd quarter. SG Americas Securities LLC now owns 10,482 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 1,986 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Halozyme Therapeutics by 1.1% in the 3rd quarter. Rhumbline Advisers now owns 217,208 shares of the biopharmaceutical company’s stock worth $3,369,000 after purchasing an additional 2,302 shares in the last quarter. Hedge funds and other institutional investors own 84.98% of the company’s stock.

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

See Also: How to build a Fibonacci channel

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.